Australian Clinical Labs Names Greg Horan as New CEO for August 2026

Leadership Transition at Australian Clinical Labs

Australian Clinical Labs (ASX:ACL) has confirmed Greg Horan as its incoming Group CEO and Executive Director, effective 31 August 2026. Horan will take over from Melinda McGrath, who is stepping down after a decade at the helm. The handover marks a significant leadership change for ACL, a company that has recently navigated market challenges and operational shifts under McGrath’s stewardship.

Horan joins ACL with a substantial track record in healthcare, having most recently served as CEO of Healthscope. There, he led a large network of 43 hospitals and thousands of employees through a period marked by post-pandemic recovery and industry transformation. His background also spans private equity and mining sectors, bringing 25 years of experience in driving strategic execution and operational discipline.

His appointment comes at a time when ACL is balancing growth ambitions with market headwinds, including wage pressures and evolving healthcare demands, as outlined in its recent earnings growth and wage pressures update. The Board expressed confidence that Horan’s leadership will build on the foundations laid by McGrath, who oversaw ACL’s expansion into new diagnostic technologies and operational efficiencies.

Compensation and Incentive Structure

The terms of Horan’s contract reveal a remuneration package designed to align his interests with ACL’s performance. His base salary is set at $1 million per annum plus superannuation. Additionally, he is eligible for a Short-Term Incentive (STI) plan worth up to 70% of his base remuneration, contingent on achieving stretch performance targets. The STI payout will be a mix of cash and deferred equity, as determined by the Board.

Long-Term Incentives (LTI) are also part of the package, subject to shareholder approval at the next Annual General Meeting. The LTI opportunity could match 100% of his base remuneration, with vesting tied to performance metrics set by the Board. If shareholder approval is not granted, the Board plans to explore alternative arrangements to ensure appropriate incentives.

Horan’s contract includes a six-month notice period and post-employment restraints preventing solicitation of ACL employees or clients for 12 months within Australia. The contract also outlines termination clauses covering misconduct, breach of contract, or fundamental changes such as ACL delisting from the ASX.

Strategic Implications and Next Steps

ACL’s leadership change arrives amid ongoing efforts to enhance shareholder value, including a 10% on-market share buy-back program initiated last year and investments in AI and genomic testing driving operational improvements and revenue growth, as documented in its share buy-back program and AI and genomic testing growth updates. The Board’s emphasis on Horan’s operational execution skills suggests a focus on translating strategic initiatives into measurable outcomes.

Melinda McGrath’s departure concludes a decade of leadership that saw ACL through significant industry shifts and internal growth. Her endorsement of Horan underscores a smooth transition, with the executive team reportedly in strong shape to support the new CEO’s agenda.